AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17579949 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 60
Study 17579949 — intervention group
Group type: COMPARATOR
Intervention: One-lung ventilation (OLV)
Number of subjects: 60
Study 16480242 — intervention group
Group type: COMPARATOR
Intervention: Conventional trauma writing
Number of subjects: 177
Study 16480242 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious trauma writing
Number of subjects: 177
Study 12050277 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU/d for 8 weeks
Number of subjects: 36
Study 12050277 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU/d for 8 weeks
Number of subjects: 36
Study 12050277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10585241 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 10585241 — intervention group
Group type: COMPARATOR
Intervention: Control (implicit memory tests without midazolam)
Number of subjects: 0
Study 8943604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg intravenously
Number of subjects: 67
Study 8943604 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 67
Study 1882698 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus carbamazepine
Number of subjects: 16
Study 1882698 — intervention group
Group type: COMPARATOR
Intervention: Lithium alone
Number of subjects: 16
Study 31628006 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education intervention (home visits and education on asthma management)
Number of subjects: 901
Study 31628006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 901
Study 30928841 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week selective corrective exercises program
Number of subjects: 30
Study 27925214 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic administration of reboxetine (RBX) 8 mg/day with anodal tDCS
Number of subjects: 16
Study 27925214 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic administration of reboxetine (RBX) 8 mg/day with cathodal tDCS
Number of subjects: 16
Study 27925214 — intervention group
Group type: COMPARATOR
Intervention: Single dose of reboxetine (RBX) 8 mg with anodal tDCS
Number of subjects: 16
Study 27925214 — intervention group
Group type: COMPARATOR
Intervention: Single dose of reboxetine (RBX) 8 mg with cathodal tDCS
Number of subjects: 16
Study 25964261 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Self‐Administered 24‐Hour Recall (ASA24)
Number of subjects: 1081
Study 25964261 — intervention group
Group type: COMPARATOR
Intervention: Interviewer‐administered, Automated Multiple‐Pass Method (AMPM)
Number of subjects: 1081
Study 25964261 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA24
Number of subjects: 1081
Study 25964261 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA24/AMPM
Number of subjects: 1081
Study 25964261 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA24/ASA24
Number of subjects: 1081
Study 25964261 — intervention group
Group type: COMPARATOR
Intervention: AMPM/AMPM
Number of subjects: 1081
Study 24127181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated Education Units (DEUs)
Number of subjects: 0
Study 24127181 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical education model
Number of subjects: 0
Study 21704241 — intervention group
Group type: EXPERIMENTAL
Intervention: 105-mg fenofibric acid (fasted)
Number of subjects: 54
Study 21704241 — intervention group
Group type: COMPARATOR
Intervention: 145-mg fenofibrate (fasted)
Number of subjects: 54
Study 21704241 — intervention group
Group type: EXPERIMENTAL
Intervention: 105-mg fenofibric acid (fed)
Number of subjects: 54
Study 21704241 — intervention group
Group type: COMPARATOR
Intervention: 145-mg fenofibrate (fed)
Number of subjects: 54
Study 20015402 — intervention group
Group type: EXPERIMENTAL
Intervention: PermaNet
Number of subjects: 0
Study 20015402 — intervention group
Group type: EXPERIMENTAL
Intervention: Olyset
Number of subjects: 0
Study 20015402 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraNet
Number of subjects: 0
Study 20015402 — intervention group
Group type: COMPARATOR
Intervention: LLINs perceived not to prevent mosquito bites
Number of subjects: 0
Study 20015402 — intervention group
Group type: COMPARATOR
Intervention: LLINs allowing a pleasant night's sleep
Number of subjects: 0
Study 20015402 — intervention group
Group type: COMPARATOR
Intervention: LLINs with a soft texture
Number of subjects: 0
Study 17337289 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA or citrate plasma samples
Number of subjects: 60
Study 17337289 — intervention group
Group type: COMPARATOR
Intervention: Serum samples
Number of subjects: 60
Study 15155407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough plate
Number of subjects: 20
Study 15155407 — intervention group
Group type: COMPARATOR
Intervention: Moistened cough swab
Number of subjects: 20
Study 15155407 — intervention group
Group type: COMPARATOR
Intervention: Dry cough swab
Number of subjects: 20
Study 11319885 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (Genotropin 0.3 IU/kg/day) for 5 days before laparotomy and aortic cross-clamping for 30 min followed by lower torso revascularization for 2 h
Number of subjects: 18
Study 11319885 — intervention group
Group type: COMPARATOR
Intervention: Control (laparotomy only)
Number of subjects: 18
Study 11319885 — intervention group
Group type: COMPARATOR
Intervention: IR (laparotomy with infrarenal cross-clamping for 30 min followed by lower torso revascularization for 2 h)
Number of subjects: 18
Study 9389287 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut protein (doses ranging from 10 microg to 50 mg)
Number of subjects: 14
Study 9389287 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 14
Study 8189741 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg alcohol
Number of subjects: 30
Study 8189741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3580729 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance (2 sets of 15 repetition maximum [RM])
Number of subjects: 45
Study 3580729 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive (1 set of 15 RM)
Number of subjects: 45
Study 3580729 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength 1 (3 sets of 6 RM)
Number of subjects: 45
Study 3580729 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength 2 (1 set of 10 RM twice weekly and 1 set of 3 RM once weekly)
Number of subjects: 45
Study 31039759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethenox (ethanol 40% v/v-enoxaparin 1000 U/mL)
Number of subjects: 200
Study 31039759 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) or citrate 4% w/v
Number of subjects: 200
Study 29093246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbrokinase in combination with low molecular heparin and sequential warfarin (n=30)
Number of subjects: 60
Study 29093246 — intervention group
Group type: COMPARATOR
Intervention: Control group (low molecular heparin and sequential warfarin, n=30)
Number of subjects: 60
Study 26344824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination framed message
Number of subjects: 0
Study 26344824 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. postal mail
Number of subjects: 0
Study 26344824 — intervention group
Group type: COMPARATOR
Intervention: Organ donor, organ recipient, and waiting list narratives
Number of subjects: 0
Study 23597063 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of oral disease (dental, periodontal, mucosal, and salivary) by dental surgeons trained in periodontology at baseline.
Number of subjects: 4500
Study 23597063 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires evaluating oral hygiene habits and thirst.
Number of subjects: 4500
Study 23597063 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection on hospitalizations and mortality (total and cause-specific) according to baseline oral health status.
Number of subjects: 4500
Study 23597063 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of the association between periodontitis and risk of premature death in dialysis patients.
Number of subjects: 4500
Study 21670447 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin 120 μg/kg
Number of subjects: 186
Study 21670447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 19156086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-coated plates (versatis) applied for 12 hours during 5 days starting from the 6th day
Number of subjects: 60
Study 19156086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-coated plates (versatis)
Number of subjects: 60
Study 19156086 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 100 mg per day
Number of subjects: 60
Study 16757825 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg of rFVIIa
Number of subjects: 40
Study 16757825 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/kg of rFVIIa
Number of subjects: 40
Study 16757825 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg/kg of rFVIIa
Number of subjects: 40
Study 16757825 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg/kg of rFVIIa
Number of subjects: 40
Study 16757825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15575454 — intervention group
Group type: EXPERIMENTAL
Intervention: Social work intervention
Number of subjects: 104
Study 15575454 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 104
Study 11138916 — intervention group
Group type: EXPERIMENTAL
Intervention: One gram azithromycin monthly
Number of subjects: 318
Study 11138916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 9301553 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescence on unfixed neutrophils
Number of subjects: 57
Study 9301553 — intervention group
Group type: COMPARATOR
Intervention: Indirect immunofluorescence on ethanol fixed neutrophils
Number of subjects: 57
Study 9301553 — intervention group
Group type: COMPARATOR
Intervention: Indirect immunofluorescence on acetone fixed neutrophils
Number of subjects: 57
Study 9301553 — intervention group
Group type: COMPARATOR
Intervention: Indirect immunofluorescence on paraformaldehyde fixed neutrophils
Number of subjects: 57
Study 9301553 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescence on unfixed neutrophils or fixed cells
Number of subjects: 57
Study 8359188 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 81
Study 8359188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 3087620 — intervention group
Group type: EXPERIMENTAL
Intervention: 250‐mg phenoxymethyl penicillin taken orally twice daily for one to three years
Number of subjects: 32
Study 3087620 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets taken orally twice daily for one to three years
Number of subjects: 32
Study 30206744 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention program including usual care, multidimensional screening, verbal counselling, written instructions, home-based high-intensity functional exercise program (HIFE), and support related to cognition, mood, risk of falling, medication, nutrition and self-care.
Number of subjects: 50
Study 30206744 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and multimodal intervention program
Number of subjects: 50
Study 30206744 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 50
Study 28403961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg per day orally for 7 days starting from hCG administration)
Number of subjects: 146
Study 28403961 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication treatment)
Number of subjects: 146
Study 25920921 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum phosphorus (>5.2 mg/dL)
Number of subjects: 6797
Study 25920921 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum phosphorus (<3.6 mg/dL)
Number of subjects: 6797
Study 25920921 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum calcium (>9.5 mg/dL)
Number of subjects: 6797
Study 25920921 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum calcium (<7.9 mg/dL)
Number of subjects: 6797
Study 25920921 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum PTH (<168 pg/mL)
Number of subjects: 6797
Study 25920921 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphorus at 4.4 mg/dL, calcium at 8.8 mg/dL, PTH at 398 pg/mL
Number of subjects: 6797
Study 25920921 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreases in serum phosphorus and calcium and increases in serum PTH
Number of subjects: 6797
Study 23142957 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA repeated doses (50 mg followed by 100 mg, administered at 2 h apart)
Number of subjects: 10
Study 23142957 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA single dose (100 mg)
Number of subjects: 10
Study 23142957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21190190 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 0
Study 19133701 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month course of telephone-based collaborative care
Number of subjects: 191
Study 19133701 — intervention group
Group type: COMPARATOR
Intervention: Usual care by primary-care physician
Number of subjects: 191
Study 19133701 — intervention group
Group type: EXPERIMENTAL
Intervention: High pain interference
Number of subjects: 191
Study 16751008 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test with cabbage
Number of subjects: 17
Study 16751008 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge with cabbage
Number of subjects: 17
Study 16751008 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test with Bra o 3 (cabbage lipid transfer protein)
Number of subjects: 17
Study 16751008 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP inhibition assays with Bra o 3
Number of subjects: 17
Study 15384954 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with repaglinide plus metformin
Number of subjects: 86
Study 15384954 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with repaglinide
Number of subjects: 86
Study 11374317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 854
Study 9876226 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid spray (fluticasone propionate)
Number of subjects: 0
Study 9876226 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo nasal spray
Number of subjects: 0
Study 8024097 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative immunochemotherapy including OK-432
Number of subjects: 36
Study 8024097 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC) and UFT
Number of subjects: 36
Study 2504796 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat, low carbohydrate enteral feed
Number of subjects: 20
Study 2504796 — intervention group
Group type: COMPARATOR
Intervention: Standard isocaloric, isonitrogenous enteral feed
Number of subjects: 20
Study 820365 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen treatment for hand warts
Number of subjects: 1802
Study 820365 — intervention group
Group type: COMPARATOR
Intervention: Salicylic and lactic acids (SAL) paint for hand warts
Number of subjects: 1802
Study 820365 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent treatment with liquid nitrogen and SAL paint for hand warts
Number of subjects: 1802
Study 820365 — intervention group
Group type: EXPERIMENTAL
Intervention: SAL paint for simple plantar warts
Number of subjects: 1802
Study 820365 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin treatment for simple plantar warts
Number of subjects: 1802
Study 820365 — intervention group
Group type: EXPERIMENTAL
Intervention: SAL paint for mosaic plantar warts
Number of subjects: 1802
Study 820365 — intervention group
Group type: COMPARATOR
Intervention: 10% buffered gluteraldehyde for mosaic plantar warts
Number of subjects: 1802
Study 820365 — intervention group
Group type: COMPARATOR
Intervention: 40% benzalkonium chloride dibromide (Callusolve 40) for mosaic plantar warts
Number of subjects: 1802
Study 820365 — intervention group
Group type: COMPARATOR
Intervention: 5% 5-fluorouracil in dimethylsulfoxide for mosaic plantar warts
Number of subjects: 1802
Study 820365 — intervention group
Group type: COMPARATOR
Intervention: 5% idoxuridine in dimethylsulfoxide for mosaic plantar warts
Number of subjects: 1802
Study 820365 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice treatment with SAL paint for hand warts and simple plantar warts
Number of subjects: 1802
Study 30010086 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + NRT sampling
Number of subjects: 22
Study 30010086 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 22
Study 28169410 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol + aspirin
Number of subjects: 80
Study 28169410 — intervention group
Group type: COMPARATOR
Intervention: Placebo + aspirin
Number of subjects: 80
Study 25633468 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg mesalazine
Number of subjects: 9
Study 25633468 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid desensitization protocol
Number of subjects: 9
Study 25633468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 24154647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement drinks provided three times on intervention day, each drink providing 283.3+/‐41.8 Kcal and 13.8+/‐4.7g of protein
Number of subjects: 26
Study 24154647 — intervention group
Group type: COMPARATOR
Intervention: Control day (no nutritional supplement drinks)
Number of subjects: 26
Study 21139252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary irradiation with liquid Rhenium-188-filled balloon after cutting balloon angioplasty (CBA)
Number of subjects: 50
Study 21139252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brachytherapy)
Number of subjects: 50
Study 18326606 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP: 2 g x kg(‐1) x d(‐1))
Number of subjects: 8
Study 18326606 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (NP: 1 g x kg(‐1) x d(‐1))
Number of subjects: 8
Study 16543072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg on day 1 posttransplant
Number of subjects: 20
Study 16543072 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim 5 microg/kg daily starting on day 1 posttransplant
Number of subjects: 20
Study 15008243 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 daily administrations of cortisone acetate (3/6 of the daily dose early in the morning, 2/6 after lunch, 1/6 after dinner)
Number of subjects: 34
Study 15008243 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 daily administrations of cortisone acetate
Number of subjects: 34
Study 15008243 — intervention group
Group type: COMPARATOR
Intervention: 2 daily administrations of cortisone acetate (2/3 of the total daily dose early in the morning, 1/3 in the afternoon)
Number of subjects: 34
Study 11119193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and general anaesthesia (EPI group)
Number of subjects: 24
Study 11119193 — intervention group
Group type: COMPARATOR
Intervention: Deep opioid anaesthesia (DOA group)
Number of subjects: 24
Study 9198564 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 111
Study 9198564 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 111
Study 8198813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerisona ointment (DFV)
Number of subjects: 2
Study 8198813 — intervention group
Group type: COMPARATOR
Intervention: Nerisalic ointment (DFV + salicylic acid)
Number of subjects: 2
Study 4028620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acebutolol (25 mg)
Number of subjects: 24
Study 4028620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acebutolol (50 mg)
Number of subjects: 24
Study 4028620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acebutolol (200 mg)
Number of subjects: 24
Study 4028620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acebutolol (400 mg)
Number of subjects: 24
Study 30516501 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy and Cytoflavin in addition to standard treatment
Number of subjects: 150
Study 30516501 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (non-steroidal anti-inflammatory drugs, myorelaxants, chondroprotectors, physiotherapy)
Number of subjects: 150
Study 26086613 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC truncated at 48 hr
Number of subjects: 28
Study 26086613 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC truncated at 24 hr
Number of subjects: 28
Study 26086613 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC truncated at 12 hr
Number of subjects: 28
Study 26086613 — intervention group
Group type: COMPARATOR
Intervention: AUC truncated at 72 hr
Number of subjects: 28
Study 24844921 — intervention group
Group type: EXPERIMENTAL
Intervention: Active phototherapy with 905 nm super‐pulsed laser and 875 and 640 nm LEDs, 12 treatments
Number of subjects: 86
Study 24844921 — intervention group
Group type: COMPARATOR
Intervention: Placebo phototherapy device, 12 treatments
Number of subjects: 86
Study 24821009 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly regimen of gemcitabine (1,000 mg/m² on days 1 and 14) and carboplatin (AUC = 3 on days 1 and 14) every 28 days
Number of subjects: 40
Study 24821009 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of gemcitabine (1,000 mg/m² on days 1 and 8) and carboplatin (AUC = 5 on day 1) every 21 days
Number of subjects: 40
Study 21058850 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT) based on acceptance and commitment therapy, n = 177
Number of subjects: 311
Study 21058850 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group, n = 134
Number of subjects: 311
Study 19079276 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching TV
Number of subjects: 538